Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

School of Pharmacy : Reich Reuven

Researchers

 Last updated June 2021 - School of Pharmacy

List of Publications

(1) Filippov-Levy N, Davidson B, Reich R. The Biological Role of the Long Non-coding RNA LINK-A in Ovarian Carcinoma. Anticancer Res 2020;40(12):6677-6684.

(2) Filippov-Levy N, Reich R, Davidson B. The biological and clinical role of the long non-coding rna loc642852 in ovarian carcinoma. Int J Mol Sci 2020;21(15):1-15.

(3) Chehover M, Reich R, Davidson B. Expression of Wnt pathway molecules is associated with disease outcome in metastatic high-grade serous carcinoma. Virchows Arch 2020;477(2):249-258.

(4) Stern-Tal D, Achache H, Jacobs Catane L, Reich R, Tavor Re'em T. Novel 3D embryo implantation model within macroporous alginate scaffolds. J Biol Eng 2020;14(1).

(5) Broner EC, Onallah H, Tavor Re'Em T, Davidson B, Reich R. Role of the Exosome Secretion Machinery in Ovarian Carcinoma: In Vitro and in Vivo Models. J Oncol 2020;2020.

(6) Sherman-Samis M, Onallah H, Holth A, Reich R, Davidson B. SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma. Gynecol Oncol 2019;153(3):651-660.

(7) Onallah H, Davidson B, Reich R. Diverse Effects of Lysophosphatidic Acid Receptors on Ovarian Cancer Signaling Pathways. J Oncol 2019;2019.

(8) Onallah H, Catane LJ, Tropé CG, Hetland Falkenthal TE, Reich R, Davidson B. Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma. Virchows Arch 2018;473(4):463-470.

(9) Filippov-Levy N, Cohen-Schussheim H, Tropé CG, Hetland Falkenthal TE, Smith Y, Davidson B, et al. Expression and clinical role of long non-coding RNA in high-grade serous carcinoma. Gynecol Oncol 2018;148(3):559-566.

(10) Gutgold N, Davidson B, Catane LJ, Holth A, Hellesylt E, Tropé CG, et al. TGFβ splicing and canonical pathway activation in high-grade serous carcinoma. Virchows Arch 2017;470(6):665-678.

(11) Harel-Dassa K, Yedgar S, Tropé CG, Davidson B, Reich R. Phospholipase D messenger RNA expression and clinical role in high-grade serous carcinoma. Hum Pathol 2017;62:115-121.

(12) Broner EC, Tropé CG, Reich R, Davidson B. TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma. Hum Pathol 2017;60:180-187.

(13) Horwitz V, Davidson B, Stern D, Tropé CG, Re'Em TT, Reich R. Ezrin is associated with disease progression in ovarian carcinoma. PLoS ONE 2016;11(9).

(14) Nymoen DA, Slipicevic A, Holth A, Emilsen E, Falkenthal TEH, Tropé CG, et al. Mir-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma. Hum Pathol 2016;54:74-81.

(15) Ravid Y, Formanski M, Smith Y, Reich R, Davidson B. Uterine leiomyosarcoma and endometrial stromal sarcoma have unique miRNA signatures. Gynecol Oncol 2016;140(3):512-517.

(16) Davidson B, Holth A, Hellesylt E, Hadar R, Katz B, Tropé CG, et al. HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival. Hum Pathol 2016;48:95-101.

(17) Reich R, Hoffman A, Suresh RR, Shai O, Frant J, Maresca A, et al. Carbamoylphosphonates inhibit autotaxin and metastasis formation in vivo. J Enzyme Inhib Med Chem 2015;30(5):767-772.

(18) Veerendhar A, Cohen S, Frant J, Supuran CT, Reich R, Breuer E. Synthesis of Enantiomeric Aminoalkylcarbamoylphosphonates and Their Evaluation as Dual-Action Anticancer MMP and Carbonic Anhydrase Inhibitors. Heteroatom Chem 2015;26(4):257-269.

(19) Katz B, Tropé CG, Reich R, Davidson B. MicroRNAs in Ovarian Cancer. Hum Pathol 2015;46(9):1245-1256.

(20) Maimon A, Mogilevsky M, Shilo A, Golan-Gerstl R, Obiedat A, Ben-Hur V, et al. Mnk2 Alternative Splicing Modulates the p38-MAPK Pathway and Impacts Ras-Induced Transformation. Cell Rep 2014;7(2):501-513.

(21) Reich R, Supuran CT, Breuer E. Tumor microenvironment as target in cancer therapy. Annu Rep Med Chem 2014;49:269-284.

(22) Davidson B, Trope CG, Reich R. The role of the tumor stroma in ovarian cancer. Front Oncol 2014;4 MAY.

(23) Davidson B, Tropé CG, Reich R. The clinical and diagnostic role of microRNAs in ovarian carcinoma. Gynecol Oncol 2014;133(3):640-646.

(24) Vaksman O, Tropé C, Davidson B, Reich R. Exosome-derived miRNAs and ovarian carcinoma progression. Carcinogenesis 2014;35(9):2113-2120.

(25) Davidson B, Rosenfeld YBZ, Holth A, Hellesylt E, Tropé CG, Reich R, et al. VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival. Hum Pathol 2014;45(7):1520-1528.

(26) Davidson B, Nymoen DA, Elgaaen BV, Staff AC, Tropé CG, Kærn J, et al. BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma. Virchows Arch 2014;464(6):701-707.

(27) Vaksman O, Davidson B, Tropé C, Reich R. Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases. Hum Pathol 2013;44(12):2677-2683.

(28) Davidson B, Smith Y, Nesland JM, Kærn J, Reich R, Tropè CG. Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion. Hum Pathol 2013;44(11):2449-2460.

(29) Stavnes HT, Holth A, Don T, Kærn J, Vaksman O, Reich R, et al. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival. Gynecol Oncol 2013;129(2):358-363.

(30) Sebban S, Golan-Gerstl R, Karni R, Vaksman O, Davidson B, Reich R. Alternatively spliced lysyl oxidase-like 4 isoforms have a pro-metastatic role in cancer. Clin Exp Metastasis 2013;30(1):103-117.

(31) Davidson B, Tropé CG, Reich R. Epithelial-mesenchymal transition in ovarian carcinoma. Front Oncol 2012;2(APR).

(32) Vaksman O, Hetland TE, Trope' CG, Reich R, Davidson B. Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma. Hum Pathol 2012;43(11):2062-2069.

(33) Momic T, Cohen G, Reich R, Arlinghaus FT, Eble JA, Marcinkiewicz C, et al. Vixapatin (VP12), a C-type lectin-protein from Vipera xantina palestinae venom: Characterization as a novel anti-angiogenic compound. Toxins 2012;4(10):862-877.

(34) Reich R, Hoffman A, Veerendhar A, Maresca A, Innocenti A, Supuran CT, et al. Carbamoylphosphonates control tumor cell proliferation and dissemination by simultaneously inhibiting carbonic anhydrase IX and matrix metalloproteinase-2. Toward nontoxic chemotherapy targeting tumor microenvironment(1). J Med Chem 2012;55(17):7875-7882.

(35) Konstantinovsky S, Davidson B, Reich R. Ezrin and BCAR1/p130Cas mediate breast cancer growth as 3-D spheroids. Clin Exp Metastasis 2012;29(6):527-540.

(36) Brenne K, Nymoen DA, Reich R, Davidson B. PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma. Am J Clin Pathol 2012;137(2):240-247.

(37) Weiss I, Trope CG, Reich R, Davidson B. Hyaluronan synthase and hyaluronidase expression in serous ovarian carcinoma is related to anatomic site and chemotherapy exposure. Int J Mol Sci 2012;13(10):12925-12938.

(38) Yuan Y, Leszczynska M, Konstantinovsky S, Tropé CG, Reich R, Davidson B. Netrin-4 is upregulated in breast carcinoma effusions compared to corresponding solid tumors. Diagn Cytopathol 2011;39(8):562-566.

(39) Frant J, Veerendhar A, Chernilovsky T, Nedvetzki S, Vaksman O, Hoffman A, et al. Orally Active, Antimetastatic, Nontoxic Diphenyl Ether-Derived Carbamoylphosphonate Matrix Metalloproteinase Inhibitors. ChemMedChem 2011;6(8):1471-1477.

(40) Vaksman O, Stavnes HT, Kærn J, Trope CG, Davidson B, Reich R. miRNA profiling along tumour progression in ovarian carcinoma. J Cell Mol Med 2011;15(7):1593-1602.

(41) Reich R, Hadar S, Davidson B. Expression and clinical role of protein of regenerating liver (PRL) phosphatases in ovarian carcinoma. Int J Mol Sci 2011;12(2):1133-1145.

(42) Revel A, Achache H, Stevens J, Smith Y, Reich R. MicroRNAs are associated with human embryo implantation defects. Hum Reprod 2011;26(10):2830-2840.

(43) Davidson B, Reich R, Trope CG, Wang T-, Shih I-. New determinates of disease progression and outcome in metastatic ovarian carcinoma. Histol Histopathol 2010;25(12):1591-1609.

(44) Achache H, Tsafrir A, Prus D, Reich R, Revel A. Defective endometrial prostaglandin synthesis identified in patients with repeated implantation failure undergoing in vitro fertilization. Fertil Steril 2010;94(4):1271-1278.

(45) Lubetzky R, Mandel D, Mimouni FB, Herman L, Reich R, Reif S. MMP-2 and MMP-9 and their tissue inhibitor in preterm human milk. J Pediatr Gastroenterol Nutr 2010;51(2):210-212.

(46) Bunkholt Elstrand M, Dong HP, Ødegaard E, Holth A, Elloul S, Reich R, et al. Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma. Hum Pathol 2010;41(6):794-804.

(47) Elloul S, Vaksman O, Stavnes HT, Trope CG, Davidson B, Reich R. Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions. Clin Exp Metastasis 2010;27(3):161-172.

(48) Veerendhar A, Reich R, Breuer E. Phosphorus based inhibitors of matrix metalloproteinases. C R Chim 2010;13(8-9):1191-1202.

(49) Shatz M, Lustig G, Reich R, Liscovitch M. Caveolin-1 mutants P132L and Y14F are dominant negative regulators of invasion, migration and aggregation in H1299 lung cancer cells. Exp Cell Res 2010;316(10):1748-1762.

(50) Kohan M, Puxeddu I, Reich R, Levi-Schaffer F, Berkman N. Eotaxin-2/CCL24 and eotaxin-3/CCL26 exert differential profibrogenic effects on human lung fibroblasts. Ann Allergy Asthma Immunol 2010;104(1):66-72.

(51) Davidson B, Hadar R, Stavnes HT, Trope' CG, Reich R. Expression of the peroxisome proliferator-activated receptors-α, -β, and -γ in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival. Hum Pathol 2009;40(5):705-713.

(52) Sebban S, Davidson B, Reich R. Lysyl oxidase-like 4 is alternatively spliced in an anatomic site-specific manner in tumors involving the serosal cavities. Virchows Arch 2009;454(1):71-79.

(53) Koler M, Achache H, Tsafrir A, Smith Y, Revel A, Reich R. Disrupted gene pattern in patients with repeated in vitro fertilization (IVF) failure. Hum Reprod 2009;24(10):2541-2548.

(54) Rayhman O, Klipper E, Muller L, Davidson B, Reich R, Meidan R. Small interfering RNA molecules targeting endothelin-converting enzyme-1 inhibit endothelin-1 synthesis and the invasive phenotype of ovarian carcinoma cells. Cancer Res 2008;68(22):9265-9273.

(55) Ravid D, Chuderland D, Landsman L, Lavie Y, Reich R, Liscovitch M. Filamin A is a novel caveolin-1-dependent target in IGF-I-stimulated cancer cell migration. Exp Cell Res 2008;314(15):2762-2773.

(56) Hoffman A, Qadri B, Frant J, Katz Y, Bhusare SR, Breuer E, et al. Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor - Synthesis and pharmacodynamic and pharmacokinetic analysis (Journal of Medicinal Chemistry (2008) 51, (1408)). J Med Chem 2008;51(14):4357-4358.

(57) Gorovetz M, Schwob O, Krimsky M, Yedgar S, Reich R. MMP production in human fibrosarcoma cells and their invasiveness are regulated by group IB secretory phospholipase A2 receptor-mediated activation of cytosolic phospholipase A2. Front Biosci 2008;13(5):1917-1925.

(58) Kleinberg L, Holth A, Trope CG, Reich R, Davidson B. Claudin upregulation in ovarian carcinoma effusions is associated with poor survival. Hum Pathol 2008;39(5):747-757.

(59) Beylis I, Frant J, Mussai N, Reich R, Breuer E. Carbamoylphosphonates part 7. An efficient method for the synthesis of hindered carbamoylphosphonates using 4-nitrophenoxycarbonylphosphonate diesters. Tetrahedron Lett 2008;49(18):2875-2877.

(60) Hoffman A, Qadri B, Frant J, Katz Y, Bhusare SR, Breuer E, et al. Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor-synthesis and pharmacodynamic and pharmacokinetic analysis. J Med Chem 2008;51(5):1406-1414.

(61) Davidson B, Hadar R, Schlossberg A, Sternlicht T, Slipicevic A, Skrede M, et al. Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma. Hum Pathol 2008;39(1):87-95.

(62) Davidson B, Shafat I, Risberg B, Ilan N, Trope' CG, Vlodavsky I, et al. Heparanase expression correlates with poor survival in metastatic ovarian carcinoma. Gynecol Oncol 2007;104(2):311-319.

(63) Davidson B, Tropé CG, Reich R. Cell adhesion and matrixassociated proteins in ovarian carcinoma. Prognostic and Predictive Factors in Gynecologic Cancers; 2007. p. 101-124.

(64) Gorovetz M, Baekelandt M, Berner A, Trope' CG, Davidson B, Reich R. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma. Gynecol Oncol 2006;103(3):831-840.

(65) Sivertsen S, Hadar R, Elloul S, Vintman L, Bedrossian C, Reich R, et al. Expression of Snail, Slug and Sip1 in malignant mesothelioma effusions is associated with matrix metalloproteinase, but not with cadherin expression. Lung Cancer 2006;54(3):309-317.

(66) Elloul S, Silins I, Tropé CG, Benshushan A, Davidson B, Reich R. Expression of E-cadherin transcriptional regulators in ovarian carcinoma. Virchows Arch 2006;449(5):520-528.

(67) Davidson B, Konstantinovsky S, Kleinberg L, Nguyen MTP, Bassarova A, Kvalheim G, et al. The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma. Gynecol Oncol 2006;102(3):453-461.

(68) Cohen-Sela E, Rosenzweig O, Gao J, Epstein H, Gati I, Reich R, et al. Alendronate-loaded nanoparticles deplete monocytes and attenuate restenosis. J Control Release 2006;113(1):23-30.

(69) Rosenzweig T, Ziv-Av A, Xiang C, Lu W, Cazacu S, Taler D, et al. Related to testes-specific, vespid, and pathogenesis protein-1 (RTVP-1) is overexpressed in gliomas and regulates the growth, survival, and invasion of glioma cells. Cancer Res 2006;66(8):4139-4148.

(70) Alpert E, Gruzman A, Lardi-Studler B, Cohen G, Reich R, Sasson S. Cyclooxygenase-2 (PTGS2) inhibitors augment the rate of hexose transport in L6 myotubes in an insulin-and AMPKα-independent manner. Diabetologia 2006;49(3):562-570.

(71) Ødegaard E, Staff AC, Kærn J, Flørenes VA, Kopolovic J, Tropé CG, et al. The AP-2γ transcription factor is upregulated in advanced-stage ovarian carcinoma. Gynecol Oncol 2006;100(3):462-468.

(72) Davidson B, Risberg B, Berner A, Bedrossian CWM, Reich R. The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma. Semin Diagn Pathol 2006;23(1):35-43.

(73) Puxeddu I, Bader R, Piliponsky AM, Reich R, Levi-Schaffer F, Berkman N. The CC chemokine eotaxin/CCL11 has a selective profibrogenic effect on human lung fibroblasts. J Allergy Clin Immunol 2006;117(1):103-110.

(74) Tessone A, Feinberg MS, Barbash IM, Reich R, Holbova R, Richmann M, et al. Effect of matrix metalloproteinase inhibition by doxycycline on myocardial healing and remodeling after myocardial infarction. Cardiovasc Drugs Ther 2005;19(6):383-390.

(75) Reich R, Vintman L, Nielsen S, Kærn J, Bedrossian C, Berner A, et al. Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities. Diagn Cytopathol 2005;33(5):332-337.

(76) Konstantinovsky S, Nielsen S, Vyberg M, Kvalheim G, Nesland JM, Reich R, et al. Angiogenic molecule expression is downregulated in effusions from breast cancer patients. Breast Cancer Res Treat 2005;94(1):71-80.

(77) Cohen S, Katz Y, Reich R, Breuer E. Trans-(4-Methylcyclohexylcarbamoyl)phosphonic acid: A representative matrix metalloproteinase (MMP) inhibitor. Acta Crystallogr Sect E Struct Rep Online 2005;61(9):o3008-o3010.

(78) Haimov-Kochman R, Ravhon A, Prus D, Greenfield C, Finci-Yeheskel Z, Goldman-Wohl DS, et al. Expression and regulation of Sprouty-2 in the granulosa-lutein cells of the corpus luteum. Mol Hum Reprod 2005;11(8):537-542.

(79) Schaner ME, Davidson B, Skrede M, Reich R, Flørenes VA, Risberg B, et al. Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients. Mol Cancer 2005;4.

(80) Davidson B, Vintman L, Nielsen S, Reich R, Berner A. Site-related expression of metastasis-associated and signaling molecules in malignant mesothelioma - A new model for the study of tumor biology and disease progression. Lung Cancer 2005;49(SUPPL. 1):S89-S93.

(81) Haimov-Kochman R, Prus D, Zcharia E, Goldman-Wohl DS, Natanson-Yaron S, Greenfield C, et al. Spatiotemporal expression of heparanase during human and rodent ovarian folliculogenesis. Biol Reprod 2005;73(1):20-28.

(82) Givant-Horwitz V, Davidson B, Reich R. Laminin-induced signaling in tumor cells. Cancer Lett 2005;223(1):1-10.

(83) Vintman L, Nielsen S, Berner A, Reich R, Davidson B. Mitogen-activated protein kinase expression and activation does not differentiate benign from malignant mesothelial cells. Cancer 2005;103(11):2427-2433.

(84) Reif S, Somech R, Brazovski E, Reich R, Belson A, Konikoff FM, et al. Matrix metalloproteinases 2 and 9 are markers of inflammation but not of the degree of fibrosis in chronic hepatitis C. Digestion 2005;71(2):124-130.

(85) Reich R, Katz Y, Hadar R, Breuer E. Carbamoylphosphonate matrix metalloproteinase inhibitors 3: In vivo evaluation of cyclopentylcarbamoylphosphonic acid in experimental metastasis and angiogenesis. Clin Cancer Res 2005;11(10):3925-3929.

(86) Elloul S, Elstrand MB, Nesland JM, Tropé CG, Kvalheim G, Goldberg I, et al. Snail, slug, and smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer 2005;103(8):1631-1643.

(87) Breuer E, Frant J, Reich R. Recent non-hydroxamate matrix metalloproteinase inhibitors. Expert Opin Ther Pat 2005;15(3):253-269.

(88) Nedvetzki S, Gonen E, Assayag N, Reich R, Williams RO, Thurmond RL, et al. RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: A different interpretation of redundancy. Proc Natl Acad Sci U S A 2004;101(52):18081-18086.

(89) Davidson B, Konstantinovsky S, Nielsen S, Dong HP, Berner A, Vyberg M, et al. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: A novel model for tumor progression. Clin Cancer Res 2004;10(21):7335-7346.

(90) Davidson B, Goldberg I, Tell L, Vigdorchik S, Baekelandt M, Berner A, et al. The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions. Clin Exp Metastasis 2004;21(3):191-199.

(91) Breuer E, Katz Y, Hadar R, Reich R. Carbamoylphosphonate MMP inhibitors. Part 4: The influence of chirality and geometrical isomerism on the potency and selectivity of inhibition. Tetrahedron Asymmetry 2004;15(15):2415-2420.

(92) Reif S, Aeed H, Shilo Y, Reich R, Kloog Y, Kweon YO, et al. Treatment of thioacetamide-induced liver cirrhosis by the Ras antagonist, farnesylthiosalicylic acid. J Hepatol 2004;41(2):235-241.

(93) Offen D, Gilgun-Sherki Y, Barhum Y, Benhar M, Grinberg L, Reich R, et al. A low molecular weight copper chelator crosses the blood-brain barrier and attenuates experimental autoimmune encephalomyelitis. J Neurochem 2004;89(5):1241-1251.

(94) Breuer E, Salomon CJ, Katz Y, Chen W, Lu S, Röschenthaler G-, et al. Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids. J Med Chem 2004;47(11):2826-2832.

(95) Givant-Horwitz V, Davidson B, Reich R. Laminin-induced signaling in tumor cells: The role of the Mr 67,000 laminin receptor. Cancer Res 2004;64(10):3572-3579.

(96) Givant-Horwitz V, Davidson B, Goderstad JM, Nesland JM, Tropé CG, Reich R. The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma. Gynecol Oncol 2004;93(2):517-523.

(97) Davidson B, Reich R, Lazarovici P, Flørenes VA, Risberg B, Nielsen S, et al. Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma. Lung Cancer 2004;44(2):159-165.

(98) Ali HA, Berkovitz R, Reich R, Srebnik M. Matrix metallo-proteinase (MMP-2) organoboronate inhibitors. Arch Pharm 2004;337(4):183-187.

(99) Farkas E, Katz Y, Bhusare S, Reich R, Röschenthaler G-, Königsmann M, et al. Carbamoylphosphonate-based matrix metalloproteinase inhibitor metal complexes: Solution studies and stability constants. Towards a zinc-selective binding group. J Biol Inorg Chem 2004;9(3):307-315.

(100) Reichenstein M, Reich R, Lehoux J-, Hanukoglu I. ACTH induces TIMP-1 expression and inhibits collagenase in adrenal cortex cells. Mol Cell Endocrinol 2004;215(1-2):109-114.

(101) Al-Quntar AA-, Baum O, Reich R, Srebnik M. Recently synthesized class of vinylphosphonates as potent matrix metalloproteinase (MMP-2) inhibitors. Arch Pharm 2004;337(2):76-80.

(102) Flørenes VA, Mælandsmo GM, Holm R, Reich R, Lazarovici P, Davidson B. Expression of activated TrkA protein in melanocytic tumors: Relationship to cell profileration and clinical outcome. Am J Clin Pathol 2004;122(3):412-420.

(103) Davidson B, Reich R, Lazarovici P, Flørenes VA, Nielsen S, Nesland JM. Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma. Breast Cancer Res Treat 2004;83(2):119-128.

(104) Davidson B, Vintman L, Zcharia E, Bedrossian C, Berner A, Ielsen S, et al. Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma. Clin Exp Metastasis 2004;21(5):469-476.

(105) Givant-Horwitz V, Davidson B, Van De Putte G, Dong HP, Goldberg I, Amir S, et al. Expression of the 67 kDa laminin receptor and the α6 integrin subunit in serous ovarian carcinoma. Clin Exp Metastasis 2003;20(7):599-609.

(106) Davidson B, Givant-Horwitz V, Lazarovici P, Risberg B, Nesland JM, Trope CG, et al. Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): Co-expression in metastatic serous ovarian carcinoma. Clin Exp Metastasis 2003;20(7):621-631.

(107) Givant-Horwitz V, Davidson B, Lazarovici P, Schaefer E, Nesland JM, Tropé CG, et al. Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions. Gynecol Oncol 2003;91(1):160-172.

(108) Davidson B, Goldberg I, Reich R, Tell L, Dong HP, Trope' CG, et al. αv- and β1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. Gynecol Oncol 2003;90(2):248-257.

(109) Davidson B, Reich R, Lazarovici P, Nesland JM, Skrede M, Risberg B, et al. Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma. Clin Cancer Res 2003;9(6):2248-2259.

(110) Davidson B, Goldberg I, Berner A, Kristensen GB, Reich R. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin Exp Metastasis 2003;20(2):161-169.

(111) Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Reich R. PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma. Clin Cancer Res 2003;9(4):1412-1419.

(112) Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Risberg B, Ben-Baruch G, et al. Coordinated expression of integrin subunits, matrix metalloproteinases (MMP), angiogenic genes and Ets transcription factors in advanced-stage ovarian carcinoma: A possible activation pathway? Cancer Metastasis Rev 2003;22(1):103-115.

(113) Davidson B, Risberg B, Reich R, Berner A. Effusion cytology in ovarian cancer: New molecular methods as aids to diagnosis and prognosis. Clin Lab Med 2003;23(3):729-754.

(114) Davidson B, Goldberg I, Givant-Horwitz V, Nesland JM, Berner A, Bryne M, et al. Caveolin-1 expression in ovarian carcinoma is MDR1 independent. Am J Clin Pathol 2002;117(2):225-234.

(115) Danenberg HD, Fishbein I, Gao J, Mönkkönen J, Reich R, Gati I, et al. Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits. Circulation 2002;106(5):599-605.

(116) Garbuzenko E, Nagler A, Pickholtz D, Gillery P, Reich R, Maquart FX, et al. Human mast cells stimulate fibroblast proliferation, collagen synthesis and lattice contraction: A direct role for mast cells in skin fibrosis. Clin Exp Allergy 2002;32(2):237-246.

(117) Pergament I, Reich R, Srebnik M. Novel matrix metallo-proteinase (MMP-2) phosphonoboronate inhibitors. Bioorg Med Chem Lett 2002;12(8):1215-1218.

(118) Davidson B, Reich R, Kopolovic J, Berner A, Nesland JM, Kristensen GB, et al. Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions. Clin Exp Metastasis 2002;19(2):135-144.

(119) Wormser U, Brodsky B, Reich R. Topical treatment with povidone iodine reduces nitrogen mustard-induced skin collagenolytic activity. Arch Toxicol 2002;76(2):119-121.

(120) Alpert E, Gruzman A, Totary H, Kaiser N, Reich R, Sasson S. A natural protective mechanism against hyperglycaemia in vascular endothelial and smooth-muscle cells: Role of glucose and 12-hydroxyeicosatetraenoic acid. Biochem J 2002;362(2):413-422.

(121) Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Nesland JM, et al. The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma. Mol Cell Endocrinol 2002;187(1-2):39-45.

(122) Davidson B, Reich R, Risberg B, Nesland JM. The biological role and regulation of matrix metalloproteinases (MMP) in cancer. Arkh Patol 2002;64(3):47-53.

(123) Fiucci G, Ravid D, Reich R, Liscovitch M. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 2002;21(15):2365-2375.

(124) Margolin L, Fishbein I, Banai S, Golomb G, Reich R, Perez LS, et al. Metalloproteinase inhibitor attenuates neointima formation and constrictive remodeling after angioplasty in rats: Augmentative effect of αvβ3 receptor blockade. Atherosclerosis 2002;163(2):269-277.

(125) Davidson B, Risberg B, Goldberg I, Nesland JM, Berner A, Tropé CG, et al. Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome. Am J Surg Pathol 2001;25(12):1493-1500.

(126) Davidson B, Reich R, Berner A, Givant-Horwitz V, Goldberg I, Risberg B, et al. Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels. Eur J Cancer 2001;37(16):2040-2049.

(127) Micera A, Vigneti E, Pickholtz D, Reich R, Pappo O, Bonini S, et al. Nerve growth factor displays stimulatory effects on human skin and lung fibroblasts, demonstrating a direct role for this factor in tissue repair. Proc Natl Acad Sci U S A 2001;98(11):6162-6167.

(128) Even-Ram SC, Maoz M, Pokroy E, Reich R, Katz B-, Gutwein P, et al. Tumor Cell Invasion Is Promoted by Activation of Protease Activated Receptor-1 in Cooperation with the αvβ5 Integrin. J Biol Chem 2001;276(14):10952-10962.

(129) Davidson B, Goldberg I, Berner A, Nesland JM, Givant-Horwitz V, Bryne M, et al. Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions. Am J Clin Pathol 2001;115(4):517-524.

(130) Goldberg I, Kopolovic J, Gotlieb WH, Ben-Baruch G, Davidson B, Berner A, et al. αv integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma. Clin Cancer Res 2001;7(12):4073-4079.

(131) Davidson B, Nesland JM, Goldberg I, Kopolovic J, Gotlieb WH, Bryne M, et al. Caveolin-1 expression in advanced-stage ovarian carcinoma - A clinicopathologic study. Gynecol Oncol 2001;81(2):166-171.

(132) Davidson B, Nesland JM, Berner A, Risberg B, Goscinski M, Tropé CG, et al. Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients. Clin Cancer Res 2001;7(11):3457-3464.

(133) Davidson B, Berner A, Nesland JM, Davidson B, Berner A, Nesland JM, et al. Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma. Clin Cancer Res 2001;7(3):551-557.

(134) Sasson S, Davarashvili A, Reich R. Role of lipoxygenase in the regulation of glucose transport in aortic vascular cells. Adv Exp Med Biol 2000;469:377-383.

(135) Elkin M, Miao H-, Nagler A, Aingorn E, Reich R, Hemo I, et al. Halofuginone: A potent inhibitor of critical steps in angiogenesis progression. FASEB J 2000;14(15):2477-2485.

(136) Davidson B, Goldberg I, Kopolovic J, Gotlieb WH, Givant-Horwitz V, Nesland JM, et al. Expression of angiogenesis-related genes in ovarian carcinoma - A clinicopathologic study. Clin Exp Metastasis 2000;18(6):501-508.

(137) Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Nesland JM, et al. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis 1999;17(10):799-808.

(138) Levi-Schaffer F, Garbuzenko E, Rubin A, Reich R, Pickholz D, Gillery P, et al. Human eosinophils regulate human lung- and skin-derived fibroblast properties in vitro: A role for transforming growth factor β (TGF-β). Proc Natl Acad Sci U S A 1999;96(17):9660-9665.

(139) Elkin M, Reich R, Nagler A, Aingorn E, Pines M, De-Groot N, et al. Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone. Clin Canc Res 1999;5(8):1982-1988.

(140) Tsafriri A, Reich R. Molecular aspects of mammalian ovulation. Exp Clin Endocrinol Diabetes 1999;107(1):1-11.

(141) Davidson B, Goldberg I, Kopolovic J, Lerner-Geva L, Gotlieb WH, Ben-Baruch G, et al. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma - A clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol 1999;73(3):372-382.

(142) Davidson B, Goldberg I, Kopolovic J, Lerner-Geva L, Gotlieb WH, Weis B, et al. Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix - Clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol 1999;72(3):380-386.

(143) Migdal M, Huppertz B, Tessler S, Comforti A, Shibuya M, Reich R, et al. Neuropilin-1 is a placenta growth factor-2 receptor. J Biol Chem 1998;273(35):22272-22278.

(144) Even-Ram S, Uziely B, Cohen P, Grisaru-Granovsky S, Maoz M, Ginzburg Y, et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 1998;4(8):909-914.

(145) Abramovitch R, Neeman M, Reich R, Stein I, Keshet E, Abraham J, et al. Intercellular communication between vascular smooth muscle and endothelial cells mediated by heparin-binding epidermal growth factor-like growth factor and vascular endothelial growth factor. FEBS Lett 1998;425(3):441-447.

(146) Dinney CPN, Bielenberg DR, Perrotte P, Reich R, Eve BY, Bucana CD, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-α administration. Cancer Res 1998;58(4):808-814.

(147) Davidson B, Goldberg I, Liokumovich P, Kopolovic J, Gotlieb WH, Lerner-Geva L, et al. Expression of metalloproteinases and their inhibitors in adenocarcinoma of the uterine cervix. Int J Gynecol Pathol 1998;17(4):295-301.

(148) Luca M, Huang S, Gershenwald JE, Singh RK, Reich R, Bar-Eli M. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol 1997;151(4):1105-1113.

(149) Xie S, Luca M, Huang S, Gutman M, Reich R, Johnson JP, et al. Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Res 1997;57(11):2295-2303.

(150) Sasson S, Kredy-Farahan L, Kaiser N, Reich R. Bovine vascular cells and extracellular matrix interactions: Dual effect of hyperglycemia. Exp Clin Endocrinol Diabetes 1997;105(SUPPL. 3):54-56.

(151) Singh RK, Reich R, Radinsky R, Berry KK, Dave BJ, Fidler IJ. Expression of basic fibroblast growth factor is necessary but insufficient for production of metastasis. Int J Oncol 1997;10(1):23-31.

(152) Tsafrin A, Reich R. Tissue remodeling in ovulation: Molecular regulation. Gynecol Endocrinol 1996;10(SUPPL. 4):61-63.

(153) Reich R, Martin GR. Identification of arachidonic acid pathways required for the invasive and metastatic activity of malignant tumor cells. Prostaglandins 1996;51(1):1-17.

(154) Williger B-, Reich R, Neeman M, Bercovici T, Liscovitch M. Release of gelatinase A (matrix metalloproteinase 2) induced by photolysis of caged phosphatidic acid in HT 1080 metastatic fibrosarcoma cells. J Biol Chem 1995;270(50):29656-29659.

(155) Singh RK, Gutman M, Reich R, Bar-Eli M. Ultraviolet B Irradiation Promotes Tumorigenic and Metastatic Properties in Primary Cutaneous Melanoma via Induction of Interleukin 8. Cancer Res 1995;55(16):3669-3674.

(156) Reich R, Blumenthal M, Liscovitch M. Role of phospholipase D in laminin-induced production of gelatinase A (MMP-2) in metastatic cells. Clin Exp Metast 1995;13(2):134-140.

(157) Chun Sang Young, Reich R, Spiess S, Pitzel L, Wuttke W, Tsafriri A. Localization of interstitial collagenase gene expression in gilt preovulatory follicles. Endocrine 1993;1(6):481-486.

(158) Iwamoto Y, Reich R, Nemeth G, Yamada Y, Martin GR. Cyclic AMP decreases chemotaxis, invasiveness and lung colonization of H-ras transformed mouse fibroblasts. Clin Exp Metast 1993;11(6):492-501.

(159) Hirsch B, Leonhardt S, Jarry H, Reich R, Tsafriri A, Wuttke W. In vivo measurement of rat ovarian collagenolytic activities. Endocrinology 1993;133(6):2761-2765.

(160) Yagel S, Geva TE, Solomon H, Shimonovitz S, Reich R, Finci-Yeheskel Z, et al. High levels of human chorionic gonadotropin retard first trimester trophoblast invasion in vitro by decreasing urokinase plasminogen activator and collagenase activities. J Clin Endocrinol Metab 1993;77(6):1506-1511.

(161) Chun S-, Popliker M, Reich R, Tsafriri A. Localization of preovulatory expression of plasminogen activator inhibitor type-1 and tissue inhibitor of metalloproteinase type-1 mRNAs in the rat ovary. Biol Reprod 1992;47(2):245-253.

(162) Brodt P, Reich R, Moroz LA, Chambers AF. Differences in the repertoires of basement membrane degrading enzymes in two carcinoma sublines with distinct patterns of site-selective metastasis. Biochim Biophys Acta Mol Basis Dis 1992;1139(1-2):77-83.

(163) Pluznik DH, Fridman R, Reich R. Correlation in the expression of type IV collagenase and the invasive and chemotactic abilities of mylomonocytic cells during differentiation into macrophages. Exp Hematol 1992;20(1):57-63.

(164) Kranzfelder D, Reich R, Abisogun AO, Tsafriri A. Preovulatory changes in the perifollicular capillary network in the rat: Role of eicosanoids. Biol Reprod 1992;46(3):379-385.

(165) Reich R, Daphna-Iken D, Chun SY, Popliker M, Slager R, Adelmann-Grill BC, et al. Preovulatory changes in ovarian expression of collagenases and tissue metalloproteinase inhibitor messenger ribonucleic acid: Role of eicosanoids. Endocrinology 1991;129(4):1869-1875.

(166) Frisch SM, Reich R, Collier IE, Genrich LT, Martin B, Goldberg GI. Adenovirus E1A represses protease gene expression and inhibits metastasis of human tumor cells. Oncogene 1990;5(1):75-83.

(167) Fridman R, Scott AF, Muller D, Reich R, Penno MB. The role of cell adhesion and migration in the in vitro invasiveness of mouse adrenal carcinoma cells. Invasion Metastasis 1990;10(4):208-224.

(168) Fridman R, Lacal JC, Reich R, Bonfil DR, Ahn C‐. Differential effects of phorbol ester on the in vitro invasiveness of malignant and non‐malignant human fibroblast cells. J Cell Physiol 1990;142(1):55-60.

(169) GOLDBERG GI, FRISCH SM, HE C, WILHELM SM, REICH R, COLLIER IE. Secreted Proteases: Regulation of Their Activity and Their Possible Role in Metastasis. Ann New York Acad Sci 1990;580(1):375-384.

(170) Kanemoto T, Reich R, Royce L, Greatorex D, Adler SH, Shiraishi N, et al. Identification of an amino acid sequence from the laminin A chain that stimulates metastasis and collagenase IV production. Proc Natl Acad Sci U S A 1990;87(6):2279-2283.

(171) Sank AC, Chi M, Shima T, Reich R, Martin GR. Collagenase and PDGF modulate chronic wound repair. Surg Forum 1989;40:624-627.

(172) Bonfil RD, Momiki S, Fridman R, Reich R, Reddel R, Harris CC, et al. Enhancement of the invasive ability of a transformed human bronchial epithelial cell line by 12-o-tetra-decanoyl-phorbol-13-acetate and diacylglycerol. Carcinogenesis 1989;10(12):2335-2338.

(173) Ura H, Bonfil RD, Reich R, Reddel R, Pfeifer A, Harris CC, et al. Expression of Type IV Collagenase and Procollagen Genes and Its Correlation with the Tumorigenic, Invasive, and Metastatic Abilities of Oncogene-transformed Human Bronchial Epithelial Cells. Cancer Res 1989;49(16):4615-4621.

(174) Reich R, Royce L, Martin GR. Eicosapentaenoic acid reduces the invasive and metastatic activities of malignant tumor cells. Biochem Biophys Res Commun 1989;160(2):559-564.

(175) Bonfil RD, Reddel RR, Ura H, Reich R, Fridman R, Harris CC, et al. Invasive and metastatic potential of a v-ha-ras-transformed human bronchial epithelial cell line. J Natl Cancer Inst 1989;81(8):587-594.

(176) Axelrod JH, Reich R, Miskin R. Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras-transformed NIH 3T3 cells. Mol Cell Biol 1989;9(5):2133-2141.

(177) Sank A, Chi M, Shima T, Reich R, Martin GR. Increased calcium levels alter cellular and molecular events in wound healing. Surgery (USA) 1989;106(6):1141-1148.

(178) Thompson EW, Reich R, Martin GR, Albini A. Factors regulating basement membrane invasion by tumor cells. Cancer Treat Res 1988;40:239-249.

(179) Abisogun AO, Daphna-Iken D, Reich R, Kranzfelder D, Tsafriri A. Modulatory role of eicosanoids in vascular changes during the preovulatory period in the rat. Biol Reprod 1988;38(4):756-762.

(180) Reich R, Stratford B, Klein K, Martin GR, Mueller RA, Fuller GC. Inhibitors of collagenase IV and cell adhesion reduce the invasive activity of malignant tumour cells. Ciba Found Symp 1988;141:193-210.

(181) Reich R, Thompson EW, Iwamoto Y, Martin GR, Deason JR, Fuller GC, et al. Effects of Inhibitors of Plasminogen Activator, Serine Proteinases, and Collagenase IV on the Invasion of Basement Membranes by Metastatic Cells. Cancer Res 1988;48(12):3307-3312.

(182) Thompson EW, Reich R, Shima TB, Albini A, Graf J, Martin GR, et al. Differential Regulation of Growth and Invasiveness of MCF-7 Breast Cancer Cells by Antiestrogens. Cancer Res 1988;48(23):6764-6768.

(183) Tsafriri A, Abisogun AO, Reich R. Steroids and follicular rupture at ovulation. J Steroid Biochem 1987;27(1-3):359-363.

(184) Reich R, Miskin R, Tsafriri A. Intrafollicular distribution of plasminogen activators and their hormonal regulation in vitro. Endocrinology 1986;119(4):1588-1593.

(185) Feldman E, Haberman S, Abisogun AO, Reich R, Levran D, Maschiach S, et al. Arachidonic acid metabolism in human granulosa cells: Evidence for cyclooxygenase and lipoxygenase activity in vitro. Hum Reprod 1986;1(6):353-356.

(186) Reich R, Miskin R, Tsafriri A. Follicular plasminogen activator: Involvement in ovulation. Endocrinology 1985;116(2):516-521.

(187) Reich R, Tsafriri A, Mechanic GL. The involvement of collagenolysis in ovulation in the rat. Endocrinology 1985;116(2):522-527.

(188) Reich R, Kohen F, Slager R, Tsafriri A. Ovarian lipoxygenase activity and its regulation by gonadotropin in the rat. Prostaglandins 1985;30(4):581-590.

(189) Reich R, Kohen F, Naor Z, Tsafriri A. Possible involvement of lipoxygenase products of arachidonic acid pathway in ovulation. Prostaglandins 1983;26(6):1011-1020.

(190) Laufer N, Reich R, Braw R, Shenker JG, Tsafriri A. Effect of clomiphene citrate on preovulatory rat follicles in culture. Biol Reprod 1982;27(2):463-471.

(191) Reich R, Laufer N, Lewysohn O, Cordova T, Ayalon D, Tsafriri A. In vitro effects of cannabinoids on follicular function in the rat. Biol Reprod 1982;27(1):223-231.

(192) Ben-Jonathan N, Braw RH, Laufer N, Reich R, Bahr JM, Tsafriri A. Norepinephrine in graafian follicles is depleted by follicle-stimulating hormone. Endocrinology 1982;110(2):457-461.